Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

TIAB, I have only two conclusions
1. There probably was a plan to do an interim report. But that report was not a typical interim report, more like an initial final report when all subjects had been 6 weeks in treatment.
2. The interim report as planned was about the most futile I have seen.

So, the report was to be at 6 weeks of treatment. The only way this makes any statistical [1] or any other kind of sense is if it was for all subjects. IPIX would have gotten the report no earlier than Nov 15th 2017, more likely about the same time when last subjects were finishing the treatment. Somebody wiser, please, tell me what's the utility of that kind of report, because I see none. I can't even see how one would estimate the effect of this interim analysis on final Type I error rate, but, then, I am not a professional statistician.

And a personal conclusion: If I had been the person responsible of putting in this interim/initial report and the absolute futility of my creation would have eventually dawned on me - I would have denied everything: "Wha? There never was ... Show me where it says... Oh, that's a typo. I am a bad typist, you know". The uselessness of it is on that scale. But that is what little vain PP would have done. Others, smarter ones, may disagree.